Non-GLP Toxicology & Screening – Preclinical Development Services
Fast, flexible non-GLP studies to de-risk your lead compound before committing to GLP testing
Why Non-GLP Screening Studies Matter
Readily available to guide you through the study design process and support you in accelerating your preclinical research
Before committing to a full GLP toxicology program, most sponsors need faster, more flexible studies to confirm dose range, tolerability, and translational relevance. Non-GLP screening studies let you make informed go/no-go decisions early, without the cost and lead time of a GLP-compliant program.
Our team designs non-GLP studies tailored to your molecule and development stage, applying the same scientific rigor that carries through into GLP testing when your program is ready for it.
When you’re ready to move forward, our GLP Safety Assessment team can take the same lead compound through IND-enabling testing.
Our Approach
Tailored Study Design From Discovery Through Screening
Our team applies a tailored approach to the pharmacology and toxicology aspects of your research, adjusting study design on a case-by-case basis. With a broad portfolio of methods and models, we help determine the transferability and reliability of your results, supporting the transition of your compounds from bench to clinic.
Our team can also support your clinical hypothesis using a pharmacometrics approach. Using tools such as population-based pharmacokinetic modeling (PopPK), we help you optimize your clinical setup for specific patient substrata.
Partner with an Expert to Advance Your Therapeutic Discovery.
Work with our team to evaluate your drug and target for therapeutic effects with precision and expertise
Our Capabilities
Non-GLP Pharmacology and Toxicology Capabilities
Our team is equipped to provide non-GLP preclinical studies in rodents, along with safety pharmacology studies across various in vitro model systems. An established third-party partner extends this support to non-rodent species when needed.
Our in vitro toxicology portfolio continues to expand, including new approach methodologies (NAMs) such as genetic toxicity, mutagenicity, carcinogenicity, liver toxicity, cardiotoxicity, and neurotoxicity screening.
In Vivo Pharmacology
- DMPK properties
- Therapeutic efficacy studies
- Pharmacokinetics
- MTD (Maximum Tolerated Dose) determination
- Dose-response relations
- Translational disease models
Non-GLP Toxicology
- Non-GLP single-dose toxicity (acute tolerability screening)
- Non-GLP repeated-dose toxicity (dose range-finding)
- Toxicokinetics
- Medical device biocompatibility screening
Ready for GLP-Compliant Studies?
Once your program is ready to move into IND-enabling testing, our team supports the transition into GLP-compliant toxicology, safety pharmacology, and immunotoxicology studies.
Navigate The Drug Development Pipeline
AAALAC Accreditation
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. InnoSer’s facilities in the Netherlands and Belgium have been AAALAC-accredited since 2016 and 2020, respectively. Read more about the AAALAC accreditation programme here.
Animal Welfare
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
info@innoserlaboratories.com